Believe in Drugs -- IMGN

It looks like Immunogen in back.  Positive Phase Is, more licenses, more products and wider reach.  Looks like IMGN should sustain current levels while waiting for mirvetuximab soravtansine to report study findings by early 19.

20 Apr 10 Puts are B .80 A .90 with huge OI  >14000.  If you believe in the reports this should make a nice returns next week.

They are talking next week, doesn't appear to be reporting on anything... 

http://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-presentations-aacr-annual-meeting-0

April catalyst already reported: https://www.biopharmcatalyst.com/calendars/fda-calendar

Happy Trading...